
Serigne Lo
@serinelo
ID: 744709452863942656
20-06-2016 01:52:24
13 Tweet
42 Followers
102 Following



Below is 1st of series of publictns from outstanding Melanoma Institute Australia visiting Dutch dermatologist scholar MaryAnn El Sharouni: Predicting recurrence in pts with sentinel nodeāneg #melanoma: validation of EORTC nomogram using populationābased data bjssjournals.onlinelibrary.wiley.com/doi/full/10.10⦠Serigne Lo

Congrats to Anne Cust , Serigne Lo and Alex Varey & their teams for bringing the MIA Melanoma Risk Calculators to realisation. Have you checked your melanoma risk? melanomarisk.org.au

#melanoma doesnāt stop in a pandemic- use our Melanoma Institute Australia online calculators at melanomarisk.org.au to calculate your individual risk- prevention & early detection key to saving lives! Professor Georgina Long AO (Bluesky @gvlongphdmd) Anne Cust Alex Varey Serigne Lo

Serigne Lo: the man defining the new speciality of āStatistical oncologyā! ā¦ā©The man that creates all the magic for the colleagues ā¦Professor Georgina Long AO (Bluesky @gvlongphdmd), Alex van Akkooi and colleagues at ā¦Melanoma Institute Australiaā© Glad to meet him at #ASCO22


Proud of MIA researcher @_graceattrill, lead author on this paper published in #JITC. A significant discovery by the MIA team in our quest to improve outcomes for immunotherapy-treated patients. James Wilmott #immunotherapy

In a significant step for personalised cancer treatment, a new online #ImmunotherapyOutcomesPrediction tool developed by MIA will help determine if advanced melanoma patients will respond to #immunotherapy. InĆŖs Pires da Silva @amenzies9 7news.com.au/news/public-heā¦

Today MIA launched a world-first online calculator, the #ImmunotherapyOutcomesPrediction tool, to predict an advanced melanoma patientās response to immunotherapy. A vital advance in personalising cancer treatment. Gabriella Rogers shared the story on #9News. InĆŖs Pires da Silva @amenzies9

MIA's new #ImmunotherapyOutcomesPrediction online calculator, allows oncologists to assess patient's response to immunotherapy & plan personalised treatment. Saving lives, & reducing physical, emotional & financial burden. Tom Hartley #7NEWS Sydney Health bit.ly/ImmunotherapyPā¦

A/Prof Serigne Lo leads a team responsible for the design & analysis of clinical trials, and the development of tools that guide the treatment of melanoma patients. You can deep-dive into his life and research in our latest #LabLife blog > bit.ly/4dXZrjT #melanoma
